PTPA and hematologic disorder: Although further studies are warranted to better understand how PP2A inhibition influences leukemia emergence, maintenance, and/or progression, the data reviewed herein strongly indicate that clinical trials are now imperative to evaluate the efficacy of PADs in the treatment of patients with hematologic malignancies.